|
[1]
|
Hyman, D.M., Taylor, B.S. and Baselga, J. (2017) Implementing Genome-Driven Oncology. Cell, 168, 584-599. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Rossing, M., Sørensen, C.S., Ejlertsen, B. and Nielsen, F.C. (2019) Whole Genome Sequencing of Breast Cancer. APMIS, 127, 303-315. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Nangalia, J. and Campbell, P.J. (2019) Genome Sequencing during a Patient’s Journey through Cancer. The New England Journal of Medicine, 381, 2145-2156. [Google Scholar] [CrossRef]
|
|
[4]
|
Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., Dooling, D., Dunford-Shore, B.H., McGrath, S., Hickenbotham, M., et al. (2008) DNA Sequencing of a Cytogenetically Normal Acute Myeloid Leukaemia Genome. Nature, 456, 66-72. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Campbell, P.J., Stephens, P.J., Pleasance, E.D., O’Meara, S., Li, H., Santarius, T., Stebbings, L.A., Leroy, C., Edkins, S., Hardy, C., et al. (2008) Identification of Somatically Acquired Rearrangements in Cancer Using Genome-Wide Massively Parallel Paired-End Sequencing. Nature Genetics, 40, 722-729. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Stratton, M.R., Campbell, P.J. and Futreal, P.A. (2009) The Cancer Genome. Nature, 458, 719-724. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Bentley, D.R., Balasubramanian, S., Swerdlow, H.P., Smith, G.P., Milton, J., Brown, C.G., Hall, K.P., Evers, D.J., Barnes, C.L., Bignell, H.R., Boutell, J., Bryant, J., Carter, R.J. and Keira Cheetham, R. (2008) Accurate Whole Human Genome Sequencing Using Reversible Terminator Chemistry. Nature, 456, 53-59.
|
|
[8]
|
Ross, J.P., Dion, P.A. and Rouleau, G.A. (2020) Exome Sequencing in Genetic Disease: Recent Advances and Considerations. F1000Research, 9, F1000 Faculty Rev-336. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Petersen, B.S., Fredrich, B., Hoeppner, M.P., Ellinghaus, D. and Franke, A. (2017) Opportunities and Challenges of Whole-Genome and -Exome Sequencing. BMC Genomics, 18, 14. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Botstein, D. and Risch, N. (2003) Discovering Genotypes Underlying Human Phenotypes: Past Successes for Mendelian Disease, Future Approaches for Complex Disease. Nature Genetics, 33, 228-237. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Stark, R., Grzelak, M. and Hadfield, J. (2019) RNA Sequencing: The Teenage Years. Nature Reviews Genetics, 20, 631-656. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Meyerson, M., Gabriel, S. and Getz, G. (2010) Advances in Understanding Cancer Genomes through Second-Generation Sequencing. Nature Reviews Genetics, 11, 685-696. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zhao, E.Y., Jones, M. and Jones, S.J.M. (2019) Whole-Genome Sequencing in Cancer. Cold Spring Harbor Perspectives in Medicine, 9, a034579. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Lappalainen, T., Scott, A.J., Brandt, M. and Hall, I.M. (2019) Genomic Analysis in the Age of Human Genome Sequencing. Cell, 177, 70-84. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Bulun, S.E. (2013) Uterine Fibroids. The New England Journal of Medicine, 369, 1344-1355. [Google Scholar] [CrossRef]
|
|
[16]
|
Stewart, E.A. (2015) Uterine Fibroids. The New England Journal of Medicine, 372, 1646-1655. [Google Scholar] [CrossRef]
|
|
[17]
|
Mäkinen, N., Mehine, M., Tolvanen, J., Kaasinen, E., Li, Y., Lehtonen, H.J., Gentile, M., Yan, J., Enge, M., Taipale, M., et al. (2011) MED12, the Mediator Complex Subunit 12 Gene, Is Mutated at High Frequency in Uterine Leiomyomas. Science, 334, 252-255. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
McGuire, M.M., Yatsenko, A., Hoffner, L., Jones, M., Surti, U. and Rajkovic, A. (2012) Whole Exome Sequencing in a Random Sample of North American Women with Leiomyomas Identifies MED12 Mutations in Majority of Uterine Leiomyomas. PLoS ONE, 7, e33251. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Makinen, N., Vahteristo, P., Butzow, R., Sjoberg, J. and Aaltonen, L.A. (2014) Exomic Landscape of MED12 Mutation-Negative and -Positive Uterine Leiomyomas. International Journal of Cancer, 134, 1008-1012. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Kim, S., Xu, X., Hecht, A. and Boyer, T.G. (2006) Mediator Is a Transducer of Wnt/beta-Catenin Signaling. Journal of Biological Chemistry, 281, 14066-14075. [Google Scholar] [CrossRef]
|
|
[21]
|
Mello, V. and Sundstrom, R.K. (2020) Cervical Intraepithelial Neoplasia. StatPearls, Treasure Island.
|
|
[22]
|
Zheng, M., Hou, L., Ma, Y., Zhou, L., Wang, F., Cheng, B., Wang, W., Lu, B., Liu, P., Lu, W. and Lu, Y. (2019) Exosomal let-7d-3p and miR-30d-5p as Diagnostic Biomarkers for Non-Invasive Screening of Cervical Cancer and Its Precursors. Molecular Cancer, 18, 76. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Bowden, S.J., Kalliala, I., Veroniki, A.A., Arbyn, M., Mitra, A., Lathouras, K., Mirabello, L., Chadeau-Hyam, M., Paraskevaidis, E., Flanagan, J.M. and Kyrgiou, M. (2019) The Use of Human Papillomavirus DNA Methylation in Cervical Intraepithelial Neoplasia: A Systematic Review and Meta-Analysis. EBioMedicine, 50, 246-259. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
da Fonseca, A.J., Galvão, R.S., Miranda, A.E., Ferreira, L.C.L. and Chen, Z. (2016) Comparison of Three Human Papillomavirus DNA Detection Methods: Next Generation Sequencing, Multiplex-PCR and Nested-PCR Followed by Sanger Based Sequencing. Journal of Medical Virology, 88, 888-894. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Canadian Cancer Statistics Advisory Committee (2018) Canadian Cancer Statistics 2017. Canadian Cancer Society, Toronto. http://cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on#ixzz51GNbcorhRm
|
|
[26]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2016) Cancer Statistics. CA: A Cancer Journal for Clinicians, 66, 7-30. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Vaughan, S., Coward, J.I., Bast, R.C., Berchuck, A., Berek, J.S., Brenton, J.D., Coukos, G., Crum, C.C., Drapkin, R. and Etemadmoghadam, D. (2011) Rethinking Ovarian Cancer: Recommendations for Improving Outcomes. Nature Reviews Cancer, 11, 719-725. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
SEER Ovarian Cancer.
https://seer.cancer.gov/statfacts/html/ovary.html
|
|
[29]
|
Poulet, G., Massias, J. and Taly, V. (2019) Liquid Biopsy: General Concepts. Acta Cytologica, 63, 449-455. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Chen, M. and Zhao, H. (2019) Next-Generation Sequencing in Liquid Biopsy: Cancer Screening and Early Detection. Human Genomics, 13, 34. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Siena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., et al. (2017) Dynamic Molecular Analysis and Clinical Correlates of Tumor Evolution within a Phase II Trial of Panitumumab-Based Therapy in Metastatic Colorectal Cancer. Annals of Oncology, 29, 119-126. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Wan, J.C.M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J.D., Caldas, C., Pacey, S., Baird, R. and Rosenfeld, N. (2017) Liquid Biopsies Come of Age: Towards Implementation of Circulating Tumour DNA. Nature Reviews Cancer, 17, 223. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Pereira, E., Camacho-Vanegas, O., Anand, S., Sebra, R., Catalina Camacho, S., Garnar-Wortzel, L., et al. (2015) Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival in Gynecologic Cancers. PLoS ONE, 10, e0145754. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Esteller, M. (2008) Epigenetics in Cancer. The New England Journal of Medicine, 358, 1148-1159. [Google Scholar] [CrossRef]
|
|
[35]
|
Dong, R., Yu, J., Pu, H., Zhang, Z. and Xu, X. (2012) Frequent SLIT2 Promoter Methylation in the Serum of Patients with Ovarian Cancer. Journal of International Medical Research, 40, 681-686. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Zhou, F., Ma, M., Tao, G., Chen, X., Xie, W., Wang, Y., et al. (2014) Detection of Circulating Methylated Opioid Binding Protein/Cell Adhesion Molecule-Like Gene as a Biomarker for Ovarian Carcinoma. Clinical Laboratory, 60, 759-765. [Google Scholar] [CrossRef]
|
|
[37]
|
Wu, Y., Zhang, X., Lin, L., Ma, X.P., Ma, Y.C., Liu, P.S. (2014) Aberrant Methylation of RASSF2A in Tumors and Plasma of Patients with Epithelial Ovarian Cancer. Asian Pacific Journal of Cancer Prevention, 15, 1171-1176. [Google Scholar] [CrossRef]
|
|
[38]
|
Wittenberger, T., Sleigh, S., Reisel, D., Zikan, M., Wahl, B., Alunni-Fabbroni, M., et al. (2014) DNA Methylation Markers for Early Detection of Women’s Cancer: Promise and Challenges. Epigenomics, 6, 311-327. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Harris, R.A., Wang, T., Coarfa, C., et al. (2010) Comparison of Sequencing-Based Methods to Profile DNA Methylation and Identification of Monoallelic Epigenetic Modifications. Nature Biotechnology, 28, 1097-1105. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Flanagan, J.M., Wilhelm-Benartzi, C.S., Metcalf, M., Kaye, S.B. and Brown, R. (2013) Association of Somatic DNA Methylation Variability with Progression-Free Survival and Toxicity in Ovarian Cancer Patients. Annals of Oncology, 24, 2813-2818. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Flanagan, J.M., Wilson, A., Koo, C., Masrour, N., Gallon, J., Loomis, E., et al. (2017) Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer. Clinical Cancer Research, 23, 2213-2222. [Google Scholar] [CrossRef]
|
|
[42]
|
Brasseur, K., Gévry, N. and Asselin, E. (2017) Chemoresistance and Targeted Therapies in Ovarian and Endometrial Cancers. Oncotarget, 8, 4008-4042. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Oza, A.M., Cook, A.D., Pfisterer, J., et al. (2015) Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. The Lancet Oncology, 16, 928-936. [Google Scholar] [CrossRef]
|
|
[44]
|
Perren, T.J., Swart, A.M., Pfisterer, J., et al. (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The New England Journal of Medicine, 365, 2484-2496. [Google Scholar] [CrossRef]
|
|
[45]
|
Pujade-Lauraine, E., Ledermann, J.A., Selle, F., et al. (2017) Olaparib Tablets as Maintenance Therapy in Patients with Platinum-Sensitive, Relapsed Ovarian Cancer and a BRCA1/2 Mutation (SOLO2/ENGOT-Ov21): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 18, 1274-1284. [Google Scholar] [CrossRef]
|
|
[46]
|
Guan, L.Y. and Lu, Y. (2018) New Developments in Molecular Targeted Therapy of Ovarian Cancer. Discovery Medicine, 26, 219-229.
|
|
[47]
|
Lortet-Tieulent, J., Ferlay, J., Bray, F. and Jemal, A. (2017) International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. Journal of the National Cancer Institute, 110, 354-361. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Lupini, L., Scutiero, G., Iannone, P., Martinello, R., Bassi, C., Ravaioli, N., Soave, I., Bonaccorsi, G., Lanza, G., Gafà, R., Loizzi, V., Negrini, M. and Greco, P. (2019) Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma: A Pilot Study. European Journal of Cancer Care (Engl.), 28, e13137. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
McAlpine, J., Leon-Castillo, A. and Bosse, T. (2018) The Rise of a Novel Classification System for Endometrial Carcinoma, Integration of Molecular Subclasses. The Journal of Pathology, 244, 538-549. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Yen, T.T., Wang, T.L., Fader, A.N., Shih, I.M. and Gaillard, S. (2020) Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. International Journal of Gynecological Pathology, 39, 26-35. [Google Scholar] [CrossRef]
|
|
[51]
|
Kuhn, E., et al. (2012) Identification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-Wide Analyses. Journal of the National Cancer Institute, 104, 1503-1513. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Le Gallo, M. and Bell, D.W. (2014) The Emerging Genomic Landscape of Endometrial Cancer. Clinical Chemistry, 60, 98-110. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Zhao, S., et al. (2013) Landscape of Somatic Single-Nucleotide and Copy-Number Mutations in Uterine Serous Carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 110, 2916-2921. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Mitamura, T., Dong, P., Ihira, K., Kudo, M. and Watari, H. (2019) Molecular-Targeted Therapies and Precision Medicine for Endometrial Cancer. Japanese Journal of Clinical Oncology, 49, 108-120. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Jewell, E., et al. (2006) Use of Trastuzumab in the Treatment of Metastatic Endometrial Cancer. International Journal of Gynecological Cancer, 16, 1370-1373. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Santin, A.D., et al. (2008) Trastuzumab Treatment in Patients with Advanced or Recurrent Endometrial Carcinoma Overexpressing HER2/neu. International Journal of Gynecology & Obstetrics, 102, 128-131. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Villella, J.A., et al. (2006) HER-2/neu Overexpression in Uterine Papillary Serous Cancers and Its Possible Therapeutic Implications. International Journal of Gynecological Cancer, 16, 1897-1902. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Black, J.D., Lopez, S., Cocco, E., Bellone, S., Altwerger, G., Schwab, C.L., English, D.P., Bonazzoli, E., Predolini, F., Ferrari, F., Ratner, E., Silasi, D.A., Azodi, M., Schwartz, P.E. and Santin, A.D. (2015) PIK3CA Oncogenic Mutations Represent a Major Mechanism of Resistance to Trastuzumab in HER2/neu Overexpressing Uterine Serous Carcinomas. British Journal of Cancer, 113, 1020-1026. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Fader, A.N., et al. (2018) Randomized Phase II Trial of Carboplatin-Paclitaxel versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Journal of Clinical Oncology, 36, 2044-2051.
|
|
[60]
|
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Hu, Z. and Ma, D. (2018) The Precision Prevention and Therapy of HPV-Related Cervical Cancer: New Concepts and Clinical Implications. Cancer Medicine, 7, 5217-5236. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Goodman, A. (2015) HPV Testing as a Screen for Cervical Cancer. BMJ, 350, h2372. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Hu, Z., Zhu, D., Wang, W., et al. (2015) Genome-Wide Profiling of HPV Integration in Cervical Cancer Identifies Clustered Genomic Hot Spots and a Potential Microhomology-Mediated Integration Mechanism. Nature Genetics, 47, 158-163. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Gradissimo, A. and Burk, R.D. (2017) Molecular Tests Potentially Improving HPV Screening and Genotyping for Cervical Cancer Prevention. Expert Review of Molecular Diagnostics, 17, 379-391. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Kader, T., Goode, D.L., Wong, S.Q., Connaughton, J., Rowley, S.M., Devereux, L., et al. (2016) Copy Number Analysis by Low Coverage Whole Genome Sequencing Using Ultra Low-Input DNA from Formalin-Fixed Paraffin Embedded Tumor Tissue. Genome Medicine, 8, 121. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Gusnanto, A., Taylor, C.C., Nafisah, I., Wood, H.M., Rabbitts, P. and Berri, S. (2014) Estimating Optimal Window Size for Analysis of Low-Coverage Next-Generation Sequence Data. Bioinformatics, 30, 1823-1829. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Wu, Y., Zhao, J., Dong, S., Wang, Y., Li, A., Jiang, Y., Chen, Z., Li, C., Wang, W. and Zhang, Z. (2019) Whole-Exome and RNA Sequencing Reveal Novel Insights into the Pathogenesis of HPV Associated Cervical Cancer. Cancer Biomark, 25, 341-350. [Google Scholar] [CrossRef]
|
|
[68]
|
Ren, T., Suo, J., Liu, S., Wang, S., Shu, S., Xiang, Y. and Lang, J.H. (2018) Using Low-Coverage Whole Genome Sequencing Technique to Analyze the Chromosomal Copy Number Alterations in the Exfoliative Cells of Cervical Cancer. Journal of Gynecologic Oncology, 29, e78. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Cancer Genome Atlas Research Network (2017) Integrated Genomic and Molecular Characterization of Cervical Cancer. Nature, 543, 378-384. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
Meijer, C.J.L.M. and Steenbergen, R.D.M. (2017) Gynaecological Cancer: Novel Molecular Subtypes of Cervical Cancer-Potential Clinical Consequences. Nature Reviews Clinical Oncology, 14, 397-398. [Google Scholar] [CrossRef] [PubMed]
|
|
[71]
|
Xu, M.J., Johnson, D.E. and Grandis, J.R. (2017) EGFR-Targeted Therapies in the Post-Genomic Era. Cancer and Metastasis Reviews, 36, 463-473. [Google Scholar] [CrossRef] [PubMed]
|
|
[72]
|
Frenel, J.S., Tourneau, C.L., O’Neil, B.H., Ott, P.A., Piha-Paul, S.A., Gomez-Roca, C.A., et al. (2016) Pembrolizumab in Patients with Advanced Cervical Squamous Cell Cancer: Preliminary Results from the Phase Ib KEYNOTE-028 Study. Journal of Clinical Oncology, 34, 5515. [Google Scholar] [CrossRef]
|